Vanda Pharmaceuticals Inc (VNDA)

NASDAQ
16.25
+0.23(+1.44%)
After Hours
16.25
0.00(0.00%)
- Real-time Data
  • Volume:
    345,465
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    16.10 - 16.65

VNDA Overview

Prev. Close
16.02
Day's Range
16.1-16.65
Revenue
268.31M
Open
16.1
52 wk Range
12.74-21.86
EPS
0.61
Volume
345,465
Market Cap
905.32M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
429,178
P/E Ratio
26.80
Beta
0.45
1-Year Change
22.64%
Shares Outstanding
55,712,230
Next Earnings Date
Feb 16, 2022
What is your sentiment on Vanda Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Vanda Pharmaceuticals Inc Company Profile

Employees
292

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company’s marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company’s products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellSellBuy
Technical IndicatorsStrong SellStrong SellStrong BuyStrong SellBuy
SummaryStrong SellStrong SellStrong SellStrong SellBuy
  • 🚀🚀🚀
    1
    • Why down??
      1
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.